The food regulator (FSSAI) has declared a specific batch of Nestle India’s dairy whitener as unsafe after testing a sample from The Lalit, New Delhi. The company is contesting the findings, citing technical differences in testing for phosphorus. This incident adds to recent regulatory scrutiny regarding the company’s product standards.
The Food Safety and Standards Authority of India (FSSAI) has declared a sample of Nestle India’s low-fat dairy whitener as unsafe and substandard. The sample was collected from the premises of The Lalit, a hotel in New Delhi operated by Bharat Hotels Ltd. Following the report, the regulator ordered the hotel to immediately halt the sale of the affected product batch.
Nestle India’s Defense
Nestle India is officially contesting the findings from the regulator. The company argues that the discrepancy arises from the testing methodology used to measure phosphorus levels. According to the company, phosphorus occurs naturally in milk-based ingredients, and it believes the regulator's test failed to distinguish between this natural content and added phosphorus. Nestle maintains that its manufacturing processes comply with mandatory food safety and quality benchmarks and that the product is safe for consumption.
Recurring Regulatory Context
This incident follows other regulatory checks for Nestle India in 2026. Earlier in September 2026, the company faced regulatory scrutiny regarding its infant nutrition products, specifically NAN Excella Pro Stage 1 and Lactogen Pro 1, related to biotin levels. While these are separate incidents, frequent regulatory questions regarding product standards can create a challenging environment for a major food manufacturer.
Investor Considerations
For investors, the primary concern regarding such events lies in how they affect brand reputation and regulatory relations. While a localized issue at a hotel does not automatically signal a broader manufacturing defect, persistent disagreements with food safety regulators can lead to increased legal and adjudication costs.
Investors typically monitor how the company handles these disputes, as the brand’s image relies heavily on consumer trust and perceived safety. Additionally, any evidence of systemic non-compliance, if proven, could potentially affect distribution in institutional channels like hotels or impact the company's standing with safety authorities.
Under the Food Safety and Standards Act, 2006, the business operator involved has the legal right to challenge the analyst’s report within a set timeframe. Nestle India confirmed it is actively engaging with the authorities and providing data from its testing to demonstrate compliance. The next important update for stakeholders will be the outcome of this appeal process and any further clarity provided by the regulator.